Carregando...
Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma
BACKGROUND: Thymic carcinoma is a rare cancer with minimal evidence of a survival benefit following chemotherapy. An oral fluoropyrimidine of S-1, however, is the recommended active cytotoxic chemotherapy agent for refractory thymic carcinoma based on a case series, whereas sunitinib or everolimus a...
Na minha lista:
| Publicado no: | BMC Cancer |
|---|---|
| Principais autores: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4766615/ https://ncbi.nlm.nih.gov/pubmed/26915359 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2159-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|